medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2015, Number 1

<< Back Next >>

Salud Mental 2015; 38 (1)

Cetoacidosis diabética asociada al consumo agudo de metilona en un paciente masculino de 21 años

Serrani AD

Language: Spanish
References: 34
Page: 47-52
PDF size: 297.63 Kb.


ABSTRACT

Use of methylone has risen recently, traded as a legal substitute of classic drugs, mimicking its effects. Actually it has been banned in European and American markets. The case of ketoacydotic diabetes complicated with the acute consumption of methylone is described in a 21 years’ caucasic insulin dependent male. After the ingestion of 3 capsules during a party, he presents during the dawn of January, 18th of 2012, to a Buenos Aires State suburban Hospital emergency department (Argentina). He refers having experienced dizziness, vomiting and somnolence, with ketotic breath, dehydration, high heart and breath rates and hypertermia. Lab exams showed metabolic acidosis and on the toxicologic analysis methylone level of 0.09 mg/dl was found. Patient was treated in an ICU with fluid reposition, volume restriction, insulin and potassium. Remission occurred after 48 hours. Mechanisms of action suggested include serotoninergic and noradrenergic effects and antidiuretic hormone release, which in term produce dehydration, lypolisis and ketotic bodies raise with acidosis greater than expected for hyperglicemia.
Conclusions In this case an association between acute use of methylone and ketoacidotic diabetes was found. Epidemiologic surveillance and education about potential risks of methylone use in young people are suggested, especially those who are predisposed to developing ketoacydotic diabetes.


REFERENCES

  1. ONU (Organización de Naciones Unidas). Oficina de las Naciones Unidas contra la Droga y el Delito (ONUDD). Informe Mundial sobre las Drogas 2011; Viena. Descargado el 12/02/2013; disponible en: www. unodc.org/unodc/en/data-and-analysis/WDR-2011.html

  2. EMCDDA (European Monitoring Centre for Drugs and Drug Addiction). Informe anual 2010. El problema de la drogodependencia en Europa. Observatorio Europeo de las Drogas y las Toxicomanías. 2010, Lisboa. Descargado el 12/02/2013, disponible en: www.emcdda.europa. eu/publications/annual-report/2010.

  3. UNODC (United Nations Office on Drugs and Crime).Global SMART update 2012, vol 8 (septiembre). Descargado el 14/04/2013, disponible en: https://www.unodc.org/documents/scientific/Global_SMART_Update_ 8_S_web.pdf

  4. Rohrig T. California Association of Toxicologist (CAT) Proceedings. Designer drugs, the future of drug abuse? Pharmacology of cathinones analogs AKA “Bath salts” May 5-6, 2011. Napa, Ca.

  5. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Synthetic cathinones, Drug Profiles, 2010. Descargado el 12/03/2013, disponible en: www.emcdda.europa.eu

  6. Brunt TM, Poortman A, Niesink RJ et al. Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol 2011;25:1543-1547.

  7. Patel NB. Mechanism of action of cathinone: the active ingredient of khat (Catha edulis). East Afr Med J 2000;77:329-332.

  8. Jacob P, Shulgin AT. Patent WO9639133 1996, 19. CA 126: 117961, Neurobiological Technologies Inc, USA.

  9. Drug Enforcement Administration, Department of Justice (2011). Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final order. Fed Regist 76: 65371-65375.

  10. McElrath K, O’Neill C. Experiences with mephedrone pre- and postlegislative controls: perceptions of safety and sources of supply. Int J Drug Policy 2011;22: 120-127.

  11. Pearson JM, Hargraves TL, Hair LS, Massucci CJ et al. Three fatal intoxications due to methylone. J Anal Toxicol 2012;36(6):444-451).

  12. Karila L, Reynaud M. GHB and synthetic cathinones: clinical effects and potential consequences. Drug Test Anal 2011;3(9):552-559.

  13. KItabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabet Care 2009;32:1335-1343.

  14. Namera A, Nakamoto A, Saito T, Nagao M. Colorimetric detection and chromatographic analyses of designer drugs in biological materials: a comprehensive review. Forensic Toxicol 2011;29(1):1-24.

  15. Shimizu E, Watanabe H, Kojima T, Hagiwara H et al. Combined intoxication with methylone and 5-MeO-MITP. Prog Neuropsycopharmacol Biol Psych 2007;31:288-291.

  16. Nagai F, Nonaka R, Satoh H, Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 2007;559:132-137.

  17. Lopez-Arnau R, Martinez-Clemente J, Pubill D, Escubedo E et al. Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. Br J Pharmacol 2012;167:407-420.

  18. Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsych 2012;37(5):1192-1203.

  19. Hysek CM, Simmler LD, Ineichen M, Grouzmann E et al. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“ecstasy”) in humans. Clin Pharmacol Ther 2011;90:246-250.

  20. Kamata HT, Shima N, Zaitsu K, Kamata T et al. Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica 2006;36: 709-723.

  21. Bossong MG, Van Dijk JP, Niesink RJM. Methylone and mCPP, two new drugs of abuse? Add Biol 2005;10:321-323.

  22. Joksovic P, Mellos N, van Wattum PJ, Chiles C. “Bath salts”-induced psychosis and serotonin toxicity. J Clin Psychiatry 2012;73(8):1125.

  23. Curzon G, Kantamaneni B, Callaghan N, Sullivan PA. Brain transmitter precursors and metabolites in diabetic ketoacidosis. J Neurol Neurosurg Psych 1982;45(6):489-493.

  24. Carbone PN, Carbone DL, Carstairs SD, Luzi SA. Sudden cardiac death associated with methylone use. Am J Forensic Med Pathol 2013;34(1):26-28.

  25. Seymour HR, Gilman D, Quin JD. Severe ketoacidosis complicated by ecstasy ingestion and prolonged exercise. Diabet Med 1996;13(10):908-909.

  26. Sogawa C, Sogawa N, Ohyama K, Kikura-Hanajiri R et al. Methylone and monoamine transporters: Correlation with toxicity. Curr Neuropharmacol 2011;9: 58-62.

  27. Ng RS, Darko DA, Hillson RM: Street drug use among young patients with Type 1 diabetes in the UK. Diabet Med 2004;21(3):295-296.

  28. Wong ML, Holt RIG. The potential dangers of mephedrone in people with diabetes: a case report. Drug Test Anal 2011;3:464-465.

  29. Observatorio Argentino de Drogas. Tendencias en el consumo de sustancias psicoactivas en Argentina 2004-2010, población de 16 a 65 años. 2011. Buenos Aires: Secretaría de Programación para la Prevención de la Drogadicción y la Lucha contra el Narcotráfico. Descargado el 12/05/2012, disponible en: http://www.observatorio.gov.ar/investigaciones/Estudio_ Nacional_sobre_consumo_en_poblacion_general_Argentina2010.pdf.

  30. Calafat A, Stocco P, Mendes F, Simon J et al. Characteristics and social representation of ecstasy in Europe. Palma of Mallorca: IREFREA; 1998.

  31. Degenhardt L, Barker B, Topp L. Patterns of ecstasy use. Addiction 2004;99:187-195.

  32. De Almeida SP, Silva MT. Characteristics of ecstasy users in São Paulo, Brazil. Subst Use Misuse 2005;40(3):395-404.

  33. Pearson JM, Hargraves TL, Hair LS, Massucci CJ et al. Three fatal intoxications due to methylone. J Anal Toxicol 2012;36:444-511.

  34. Lee P, Greenfield JR, Campbell LV. Mind the Gap when managing ketoacidosis in type 1 diabetes. Diabet Care 2008;31(7):e58.




2020     |     www.medigraphic.com